Thromboelastography to Monitor Clotting/Bleeding Complications in Patients Treated with the Molecular Adsorbent Recirculating System

Table 3

Demographics and laboratory data prior to MARS treatment.

Identification number	Gender (women/men)	Age (years)	Indication for MARS^1	Number of MARS sessions performed	Child Pugh Points^6	MELD Points^7	SAPS II Points^8	Number of Organs/Systems in Failure^9	Serum-Bilirubin^10 (μmol/L)	Serum-Creatinin^11 (μmol/L)	Arterial Ammonia^12 (μmol/L)	INR^13	Platelet count^14 (×10^9/L)
1	w	45	ALF^1	5	10	13	69	3	306	56	102	1.7	60
2	w	50	AoCLF^2	7	10	22	33	5	400	145	58	1.8	108
3	w	41	Pruritus^3	4	5	6	7	0	7	70		1	291
4	m	63	HRS^4	7	11	13	55	3	125	204	56	1.8	35
5	m	82	Intox^5	2	6	6	61	3	4	97	12	1	264
median		50		5	10	13	55	3	108	97	57	1.75	108

¹Acute liver failure, due to liver infiltration by lymphoma.
²Acute on chronic liver failure, the underlying liver disease was nonalcoholic steatohepatitis triggered by infection.
³Primary biliary cirrhosis with refractory pruritus.
⁴Hepatorenal syndrome due to Child-Pugh C cirrhosis attributable to alcoholic liver disease.
⁵Severe intoxication with clorazepate.
6-8According to the following publications: 6: to [12]; 7: to [13]; 8: to [14].
⁹Number of organs/systems requiring pharmacologic and/or mechanical support.
10-14Normal value/range: 10: <17 μmol/L; 11: 70–150 μmol/L; 12: <33 μmol/L; 13: <1.2; 14: 143–400 × 10⁹/L.